EyePoint FY2022 net product revenue $39.9M (+13% YoY); net loss $102.3M; cash $144.6M

EyePoint, Inc.

FY2022 net product revenue $39.9M, up 13% from $35.3M; YUTIQ revenue $28.3M (+67% vs 2021).
Net loss $102.3M ($2.74/share) vs $58.4M ($2.03/share) in FY2021; includes $20.7M DEXYCU impairment.
Cash and investments $144.6M at Dec 31, 2022; cash runway projected into 2H 2024.
Phase 2 DAVIO 2 (wet AMD) topline data expected by year-end 2023; Phase 2 PAVIA (NPDR) enrollment completion in Q4 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

EyePoint, Inc. reported the fiscal year ended December 31, 2022 results: revenue $41.4 million.

Period: the fiscal year ended December 31, 2022
Revenue: $41.4 million
Result: reported results

Exact text from the filing

For the full year ended December 31, 2022, total net revenue was $41.4 million compared to $36.9 million for the full year ended December 31, 2021.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

EyePoint, Inc. reported the quarter ended December 31, 2022 results: revenue $10.5 million, net income $43.5 million, EPS ($1.16) per share.

Period: the quarter ended December 31, 2022
Revenue: $10.5 million
Net income: $43.5 million
EPS: ($1.16) per share
Result: reported results

Exact text from the filing

For the quarter ended December 31, 2022, total net revenue was $10.5 million compared to $11.5 million for the quarter ended December 31, 2021.

View on SEC.gov

Browse all earnings releases →

EyePoint, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-005701

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.